<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174733</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6163</org_study_id>
    <secondary_id>XRP1526B/3030</secondary_id>
    <nct_id>NCT00174733</nct_id>
  </id_info>
  <brief_title>Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered for Twelve Weeks Either in a Once-Daily Regimen in the Morning (160 μg qd AM) or in a Twice Daily Regimen (80 μg Bid) in Adults and Adolescents With Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen
      in patients with mild to moderate asthma, who have previously been treated with an inhaled
      corticosteroid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 12 in FEV1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores, rescue albuterol use and morning peak flow measurements</measure>
  </secondary_outcome>
  <enrollment type="Actual">456</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide (XRP1526)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 12 years or older

          -  History of persistent bronchial asthma for at least 6 months

          -  Documented use of an inhaled steroid or a combination of an inhaled
             steroid/long-acting beta 2 agonist for at least 1 month before screening

          -  At screening, FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or
             ICS/LABA use respectively.Reversibility of FEV1 by at least 12% and 200 ml
             post-bronchodilator

          -  Be able to use oral inhalers

          -  Non-smokers

        Exclusion Criteria:

          -  History of life-threatening asthma

          -  Other pulmonary diseases; URI within 4 weeks before screening

          -  Use of systemic steroids within 1 month before screening or more than 3 times in
             previous 6 months

          -  Beta-adrenergic blocking agent use

          -  More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in
             the prior year before screening

          -  Pregnant or breast-feeding females

          -  Females of child-bearing potential not using adequate means of birth control

          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major
             systemic disease

          -  Abnormal clinical laboratory parameters that would limit participation in the study or
             interfere with interpretation of study results

          -  History of drug or alcohol abuse

          -  Treatment with any investigational product within 30 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>April 7, 2009</last_update_submitted>
  <last_update_submitted_qc>April 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Glucocorticosteroid. Bronchospasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

